The Prostate Cancer Prevention Trial (PCPT) recently demonstrated a significant reduction in prostate cancer incidence of about 25% among men taking finasteride compared to men taking placebo. However, the effect of finasteride on the natural history of prostate cancer is not well understood. We adapted a convolution model developed by Pinsky (2001) to characterize the natural history of prostate cancer in the presence and absence of finasteride. The model was applied to data from 10,995 men in PCPT who had disease status determined by interim diagnosis of prostate cancer or end-of-study biopsy. Prostate cancer cases were either screen-detected by Prostate-Specific Antigen (PSA), biopsy-detected at the end of the study, or clinically detected, that is, detected by methods other than PSA screening. The hazard ratio (HR) for the incidence of preclinical disease on finasteride versus placebo was 0.42 (95% CI: 0.20-0.58). The progression from preclinical to clinical disease was relatively unaffected by finasteride, with mean sojourn time being 16 years for placebo cases and 18.5 years for finasteride cases (p-value for difference = 0.2). We conclude that finasteride appears to affect prostate cancer primarily by preventing the emergence of new, preclinical tumors with little impact on established, latent disease.
Introduction
Progress in understanding the molecular basis for carcinogenesis is leading to an increased interest in chemopreventive approaches for cancer control. Chemoprevention trials that have been completed include the beta-carotene and retinol prevention trial (Omenn et al, 1996) , which tested whether these agents were beneficial against lung cancer in a population deemed to be at high risk of the disease, and the breast cancer prevention trial (Fisher et al, 1998) , which evaluated the efficacy of tamoxifen in preventing breast cancer. The SELECT trial (Lippman et al, 2005) , which is testing selenium and vitamin E for their protective effects in prostate cancer, is ongoing, with results expected in 2010.
The SELECT trial was preceded by the Prostate Cancer Prevention Trial(PCPT), a randomized, seven-year chemoprevention trial that tested the effects of the drug finasteride on prostate cancer incidence (Thompson et al, 2003) . Finasteride inhibits the action of the enzyme 5-alpha reductase, which converts testosterone to its active form in the prostate. Thus, finasteride deprives the prostate of the form of testosterone that it is most able to use. The results of the trial were recently published and showed that men in the finasteride arm had a significant reduction in prostate cancer diagnosis as compared to men taking a placebo.
Interpretation of the PCPT findings is highly controversial because, although the trial showed a marked decline in the frequency of a prostate cancer diagnosis, this reduction was confined entirely to low-grade cancers, with the finasteride arm showing an higher percentage as well as an increased absolute frequency of high grade disease. These results raised the question of whether finasteride, while decreasing overall incidence of disease, might be increasing the aggressiveness of tumors that do arise while on treatment. This issue has not yet been conclusively resolved.
In this article we use a class of mathematical models, the convolution models, to address how finasteride affects the natural history of prostate cancer. Convolution models decompose the incidence of diagnosed disease into the incidence of preclinical disease and the sojourn time in the preclinical state. These models were introduced for cancer screening data by Zelen and Feinleib (1969) and further developed by Louis et al (1978) , Day (1983, 1984) , Shen and Zelen (2001) and Pinsky (2001) . Convolution models have also been used by Brookmeyer and Goedert (1989) and De Gruttola and Lagakos (1989) in the context of HIV infection and incubation.
We adapt the convolution model of Pinsky (2001) to determine whether finasteride acts by affecting the onset of preclinical disease or altering the rate of disease progression from the preclinical to the clinical state. An increase in the hazard of clinical diagnosis while on finasteride is consistent with increased disease aggressiveness associated with treatment. Thus, fitting the convolution model to the PCPT data enables us to address one of the most pressing scientific questions arising from the trial. In Section 2 we describe the design of the PCPT. This section also details the Pinsky (2001) algorithm for analyzing prospective screening data and describes the adaptations made in order to fit the model to the PCPT data. In Section 3, we apply the adapted model to our data set and present our results. Section 4 concludes with a detailed discussion of our results and their interpretation.
The PCPT
The PCPT was a multi-center, randomized, double-blind study (Thompson et al, 2003) . Between October 1993 and May 1997, 18,882 healthy men, aged 55 and above, were enrolled and randomized to receive either 5 mg of finasteride per day or a placebo. Men who reported a history of prostate cancer or who exhibited symptoms of benign prostate disease were excluded, as were men with an abnormal digital rectal exam (DRE) or a PSA level above 3.0 ng/ml. The goal of including only men with low PSA's was to remove as many prevalent prostate cancer cases as possible.
Participant evaluation consisted of two clinic visits and two phone contacts per year. At each participant visit, treatment side effects were evaluated, compliance was assessed through monitoring of pill counts, and new pills were dispensed. Once a year, as part of their annual physical exam, men were required to have both a DRE and a PSA test. If either the DRE result was positive or the adjusted PSA level was above 4.0 ng/ml, a biopsy was recommended. Serum samples were sent to a central laboratory, where PSA levels were measured, and, where applicable, adjusted for finasteride use, since finasteride is known to lower PSA by approximately 50%. The adjustment consisted of multiplying the observed PSA level in the finasteride group by a factor of 2 for the first three years of the trial; thereafter, the adjustment factor was increased to 2.3 so as to achieve an equal number of interim biopsies each year on the two arms. 2,122 men in the finasteride group and 2,348 men in the placebo had a biopsy recommended during the course of the trial. Biopsy samples were sent to a central laboratory where they were analyzed by a study pathologist.
Participants not diagnosed with prostate cancer by the end of the study were asked to undergo an end-of-study biopsy. Approximately 60% of participants had endpoint information (positive for prostate cancer or negative end-of-study biopsy) by the time the trial was stopped in 2003. These participants constitute our study population.
Convolution models for natural history
In the standard convolution model for preclinical incidence and duration, the probability of being an incident case at time t is the probability of preclinical incidence at some time s prior to t, with a sojourn time of t − s. Thus, the probability density function, I(t), for incidence at time t, is written as follows: where g is the preclinical incidence density function, and f is the density for transitioning from the preclinical to the clinical state (i.e., the sojourn time density). Then, in a screened population, P j , the probability of being a screen-detected case at the j-th screen (at age t j ) is a function of the probability of entering the preclinical disease state before t j , not leaving it due to clinical presentation before t j , and of being detected with disease by the screening test at the jth screen, but not at any prior screens. Mathematically, we have:
where t 0 is the earliest age at which preclinical onset could occur, F is the cdf of the sojourn time, and β m is the sensitivity at the mth screen. This probability is conditional on not being clinically diagnosed before the start of the study (an entry criterion for most studies) and therefore should be divided by the probability of clinical diagnosis occurring after the age at randomization. Similar considerations apply for calculating I j (t), the probability of a subject presenting as a clinical case after the jth screen (and before any other screens). Specifically,
When screening occurs at regular intervals, the standard convolution model may be fit to data consisting of the observed frequency of screen and clinically detected cases at/after each screen. For interval cases occurring between screens j and j + 1, we assume that their time of diagnosis is t j * = .5(t j + t j+1 ). The observed data are {m j }, the number of cases detected at each screening test, and {n j }, the numbers of cases detected between screening tests. Then, assuming that these are distributed according to a Poisson distribution, the log-likelihood (LL) for m 1 , m 2 , . . . m k screendetected cases, and n 1 , n 2 , . . . n k clinical or interval cases is given by:
where M j is the number undergoing screening at t j , and N j is the person-years of observation between t j and t j+1 . We can use maximum likelihood techniques to estimate f, g, and β. Day (1983, 1984) used simple parametric forms for f and g. Louis et al (1978) and Etzioni and Shen (1997) used piecewise constant forms. In our modeling of the PCPT data, we follow Pinsky (2001) , who used a cubic polynomial for the hazard of preclinical onset, and incorporated other-cause mortality as a competing risk in the expressions for P j and I j above. We describe our modeling assumptions in detail in the next section.
Adapting the convolution model to the PCPT
In applying the convolution model to the PCPT data, our primary goal is to assess the effect of finasteride therapy on preclinical incidence and duration. Several features of the PCPT necessitate extending or adapting the standard model to meet this goal. First, in the standard model, the preclinical incidence density function g, or the corresponding hazard function, g * , governs the entire period of natural history. However, in the PCPT setting, for men on the treatment arm, the natural history includes both pre-treatment and post-treatment segments (men in the placebo arm have only pre-treatment segments). To address this we differentiate between the hazards of disease onset before and after trial entry. We let g * and g * D be the hazards of entering the preclinical state in the absence and presence of finasteride, respectively. Men on the treatment arm are thus governed by the hazard g * from birth until the age t E they entered the study and by g * D after the study begins. In terms of the formulas for P j and I j , we have
Similarly, let f * and f * D be the clinical hazard rates (i.e., the hazards for transitioning from the preclinical to the clinical state) in the absence and presence of finasteride, respectively. A finasteride arm participant entering the preclinical state at age s before study entry will have a clinical hazard of f * (t − s) until the start of the study and f * D (t − s) after study entry. Men entering the preclinical phase after study entry experience only the hazard f * D . With respect to the formulas for P j and I j , we have
A second important feature of PCPT that impacts our modeling approach is the fact that the trial enrolled only men with baseline PSA below 3 ng/ml and screened these men annually with PSA and DRE. As a consequence of this protocol, only a relatively small number of cases were diagnosed between screens (< 10%). This small number does not allow for stable estimation of the sojourn time distribution. To address this, we expanded our definition of symptomatic, or clinical, cases to include those men with a positive DRE, i.e., a palpable tumor; correspondingly, we also narrowed the definition of screen detected to include only those men with a positive PSA. Cases with both a positive DRE and PSA at the same exam were classified as clinically detected, since a "symptom", tumor palpability, was present at the time of the screen.
A further consequence of the requirement that baseline PSA be below 3.0 ng/ml was that the study population consisted entirely of men with PSA levels at least 1 ng/ml below the 4.0 ng/ml threshold for screen positivity. Since PSA naturally grows over time, we expected that the test sensitivity of PSA would increase over time in the trial. This is consistent with the observation of more screen detected cases in later rounds than in the first round, which is contrary to the normal pattern in a screening trial of more cases being detected on the first round of screening. Therefore, we model sensitivity as a linear function of the time since the trial began, i.e., β k = a + bk for a screen at year k of the trial.
For the purposes of the model, screen sensitivity is defined as the probablility that a man in the preclinical state who undergoes screening has a positive screen and follow-up that results in a prostate cancer diagnosis. The sensitivity estimated by the model is therefore the probability, among men with preclinical disease, of a positive PSA times the probability of having a (positive) biopsy given a positive PSA. Thus, the frequency of biopsy impacts our estimated test sensitivity. Positive screening tests that are not followed by biopsy are effectively considered as negative tests by the model. For these reasons, we refer to sensitivity as estimated by the model as "effective" sensitivity. As we have already noted, in the PCPT, only approximately 60% of screen-positive subjects followed the protocol recommendation for a prostate biopsy. Although the true sensitivity can be calculated directly based on the endof-study biopsy results with corresponding PSA results for the final screening round (Thompson et al, 2004 ; also, see Table 2 ), we do not use this in the model as it reflects a setting where 100% of subjects are biopsied following the screening test; in addition, it reflects PSA levels seven years after randomization, which, as observed above, will be higher than PSA levels at earlier years. To account for the end-ofstudy biopsy, we model it as an additional screen with 100% sensitivity.
In applying the adapted convolution model to the PCPT, we parametrize g * as a cubic polynomial, and write g *
.5]) (here t d is years on treatment). This allows for a possible effect of the duration of finasteride treatment on preclinical incidence. C is interpretable as the hazard ratio for entry into the preclinical state on finasteride relative to control at 3.5 years after the start of the trial ("preclinical hazard ratio"); if D = 0 then the preclinical hazard ratio is constant over time. We assume constant hazards f * and f * D . To fit the model, we record, for each five year age group and study arm, the number of men screened and the number of PSA-detected cases at each screening visit, the person-years of follow-up after each screen and the number of clinical cases after each screen. The likelihood is then computed as described above, and the model is fit using maximum likelihood, with confidence intervals derived using the profile likelihood method (Pinsky 2001 ).
Once we have estimated the model parameters, we utilize the estimates to generate simulated histories for a population of men with an age distribution similar to the trial population; these histories are then used to empirically calculate various quantities, such as average lead time and frequency of overdiagnosis. Specifically, for each simulated individual, we randomly generate the age of preclinical onset based on our estimate of g * (placebo) and g * D (finasteride). Then we use our estimate of f * (placebo) and f * D (finasteride) to generate an age at clinical detection. We simulate annual PSA screens as in the trial, with detection probabilities given preclinical disease based on our estimates of effective test sensitivity. The Berkeley life tables are used to generate other-cause mortality. Given these simulated life histories, we can estimate the empirical, average lead time on each arm and the frequency of overdiagnosis. The lead time is calculated as the average time from screen detection to clinical diagnosis, among men with clinical diagnosis during their lifetimes; the overdiagnosis frequency is the the proportion of screen-detected cases whose other-cause death precedes their clinical diagnosis date. These quantities can also be calculated analytically as described in Pinsky (2001); however, the calculations can become quite tedious for some of the quantities and the simulations allow additional flexibility. Other quantities of interest can be calculated analytically relatively easily; for example, the proportion of men age t who have preclinical disease at study entry is calculated as (
where G is the cumulative preclinical incidence and I C is the cumulative clinical incidence. Table 1 describes the cohort that was examined in this analysis, namely the 5,298 finasteride arm and 5,657 placebo arm men aged 55-79 at study entry with either an end of study biopsy or an interim prostate cancer diagnosis. There were 815 (15.4%) total cases in the finasteride arm versus 1189 (21.0%) in the placebo arm (p < 0.0001 ). About half of all cases were detected at the end of study biopsy. The frequency of high grade disease among study participants was significantly greater in the finasteride arm than in the placebo arm (5.5% vs. 4.3%; p = 0.006). Table 2 gives the model results. The main parameters of interest are the hazard ratio (finasteride versus placebo) for the onset of preclinical disease (preclinical HR) and the hazard ratio for progression from preclinical to clinical disease (clinical HR). The hypothesis of a constant preclinical HR for finasteride (i.e., independent of time on treatment, or equivalently, D = 0) was not rejected (p = 0.9),therefore the results shown in Table 2 the absence of competing mortality, of 18.5 and 16 years, respectively. These were not significantly different (p=0.2, likelihood ratio test). In the finasteride arm, the estimated effective sensitivity was 3.3% at the first and 5.9% at the sixth screen, while in the placebo arm the effective sensitivities were estimated at 2.9% (first screen) and 7.5% (sixth screen). Estimated sensitivities did not differ across study arms (p =0.2). Based on the fitted model, we estimated that 13.7% of men in the study already had preclinical prostate cancer at the start of the trial.
Results
Lead time and overdiagnosis frequencies were estimated for two age groups, namely men aged 55-59 and men aged 70-75 at study entry. Overdiagnosis is defined as the detection by PSA screening of a prostate cancer that, in the absence of PSA, would not have been diagnosed within the lifetime of the patient. Among PSAdetected cases in the younger age group, 40% on placebo and 42% on finasteride would not have had clinical diagnosis in their lifetimes; among men who would have been clinically diagnosed, the average lead times were 8.4 and 8.1 years for cases on finasteride and placebo respectively. In contrast, for men aged 70-75, 69% of finasteride and 66% of placebo arm participants would not have been clinically diagnosed, and average lead times were 4.9 and 4.8 years respectively. The estimated lead times are shorter for older than for younger men because they are conditional on clinical diagnosis occurring before other-cause death.
Note that the above estimates of overdiagnosis and lead time are based on the assumption that the trial regimen of annual DRE testing will continue into the future, and any palpable tumors detected will be considered clinical cases. Also, the estimates for finasteride assume continued use of the drug following the end of the seven year PCPT study period and assume that the clinical hazard rate will remain constant with extended treatment.
Discussion
In this article we have analyzed the effect of a preventive intervention (finasteride) on the natural history of prostate cancer by adapting a convolution model of natural history to the special circumstances of PCPT. The PCPT is well suited to convolution modeling because participants underwent annual PSA screening exams. Results of these exams provide information on the incidence of preclinical disease and, together with data on clinical detection (symptoms, TURP-based diagnosis, or DRE-palpable disease), allow us to estimate the preclinical sojourn time.
Our analysis demonstrates that men taking finasteride have a substantially reduced risk of developing preclinical prostate cancer as compared to men on placebo, with a hazard ratio of 0.42. This is lower than the relative risk of 0.73, which arises from the observed frequencies of prostate cancer diagnosis in the PCPT, namely 21% in the placebo and 15.4% in the finasteride arm. The difference between the two relative risks is explained by our model results, which imply that a considerable proportion of study men (13.7%) already had preclinical disease at the start of the study, notwithstanding the eligibility requirement of a baseline PSA below 3.0 ng/ml. Assuming that finasteride does not make prostate tumors disappear, the drug would have to prevent well over 50% of the newly emergent tumors in men without pre-existing prostate cancer in order to achieve the observed reduction in disease from 21% to 15.4%.
Our model results validate well with what is known about the biology of prostate cancer and the sensitivity of PSA. For example, based on our model, we estimated that the prevalence of occult prostate cancer at the start of the trial was approximately 13.7%. This model-based estimate of the prevalence of disease among men with PSA below 3.0 ng/ml and negative DRE compares closely with the results of the end-of-study biopsy, which found a prevalence of 15% among men with PSA below 4.0 ng/ml and negative DRE (Thompson et al, 2004) . Our mean sojourn time, approximately 16 years on average in the placebo group, is somewhat higher than the estimate of Etzioni et al (1999) , who estimated the mean sojourn time among pre-PSA prostate cancer cases to be approximately 12 years on average. However, we note that our study population (men with low PSA and negative DRE at the start) likely selects for a more indolent case population. A limitation of the PCPT data is the rarity of progression to true symptomatic clinical disease. Because of this, we included in the definition of clinical disease tumors that are palpable by DRE. Due to the low specificity of DRE however, this definition is imperfect; in some cases, the abnormality detected on DRE was probably unrelated to the actual cancer. However, assuming that the majority (75% or more) of DRE positive cases in each arm were truly palpable, our sojourn time results would not be greatly changed. An additional limitation is that our analysis included only those men with study biopsy. In the study, more men on finasteride dropped out early due to side effects, and these individuals did not therefore receive their end-of-study biopsy. If subjects who dropped out had a different cancer risk profile than those who remained on study, then this could lead to bias in the comparison of preclinical and clinical incidence across study arms.
A consequence of the decision to include DRE's as clinical cases is that our definition of PSA sensitivity does not correspond to the standard notion of sensitivity, which refers to the ability of the PSA test to detect disease before it becomes symptomatic. Rather, our estimates of sensitivity refer to the ability of the test to detect disease before it becomes either symptomatic or palpable on a DRE exam. Our effective sensitivity estimates are low, but recall that these depend on receipt of a biopsy, and should be interpreted in context of the results of Thompson et al (2005) , who estimated that, in the PCPT, the sensitivity of a PSA test with a cutoff of 4.0 ng/ml ws only 20%.
Chemoprevention trials in cancer are rare, expensive, and time consuming. Re- sults are typically presented in terms of the reduction in frequency of a cancer diagnosis associated with treatment. However, the patterns of disease incidence observed during the course of a prevention trial can be considerably more revealing, particularly when the trial population is subjected to regular screening for the cancer of interest. In such settings, convolution modeling can be adopted, and, where necessary, adapted, to reveal far more than the standard endpoint analysis, and even to uncover features of the mechanism of action of the preventive intervention. The present analysis illustrates this quite clearly. Indeed, our modeling results indicate that the true protective effect of finasteride on prostate cancer development may be much larger than the observed 27%, and that this effect appears to be confined mostly to the prevention of new disease and not to the progression of existing tumors. 
